US Patent 4,393,078 Landscape: Scope, Claim Boundaries, and US Patent Estate Strength for Reversing Ethanol-Impaired Mental Alertness
US Patent 4,393,078 is a US-method-of-use patent focused on reversing “impaired mental alertness effects of ethanol” by administering a specific compound of formula (I) or its pharmaceutically acceptable acid addition salt, with claim scope concentrated around oral, non-toxic administration and specific salt/carrier/capsule-tablet embodiments.
What is protected?
A method-of-treatment claim set directed to:
- a target condition defined functionally as “ethanol-impaired mental alertness effects” in a human, and
- administration of the formula (I) compound or its pharmaceutically acceptable acid addition salts (notably hydrochloride), in an effective non-toxic amount, including carrier and oral dosage form limitations.
Bottom line for businesses
- The practical enforcement perimeter is the intersection of (i) a claimed formula (I) compound (or covered salt) and (ii) an induced treatment claim to reverse ethanol-related mental alertness impairment.
- Freedom-to-operate for generics or competitors hinges on whether their candidate is the same compound (or salt) and whether their intended labeling, instructions, and marketing are structured to satisfy the claim’s “reverse impaired mental alertness” treatment framing.
What are the exact claim elements and scope limits of US Patent 4,393,078?
Core independent claim (Claim 1) defines all essential elements. Dependent claims add narrower embodiments rather than new subject matter.
Claim 1 element map (independent claim)
Claim 1 requires all of the following:
- Method: “A method of reversing the impaired mental alertness effects of ethanol in a human”
- Population: “a human who has consumed alcohol”
- Administration: “administering… an effective, non-toxic amount”
- Active: “the compound of formula (I)” or “a pharmaceutically acceptable acid addition salt thereof”
- Therapeutic intent/outcome framing: reversal of ethanol’s impaired mental alertness effects
Built-in boundary conditions (how scope tightens or broadens)
- Active ingredient tether: The method is limited to the formula (I) compound (and its covered salts). Any substitution to a different chemical structure generally avoids infringement unless the substitute falls within formula (I) definition and its salt coverage.
- Salt coverage is claimable: “pharmaceutically acceptable acid addition salt” expands coverage beyond the free base form, but remains restricted to salts of the claimed compound, not alternative actives.
- Functional disease definition: “impaired mental alertness effects of ethanol” is a functional clinical endpoint. The claim’s enforceability in practice typically tracks whether the accused use is intended to reverse that mental impairment after alcohol consumption, not merely to “reduce intoxication” broadly.
- Non-toxic effective amount: establishes a pharmacologic dosage boundary; infringers can attempt to design around using non-effective or toxic dosing profiles, though such strategies are rarely commercially viable.
Does Claim 2-9 add meaningful scope or only narrow embodiments of the same method?
Claim 2 to Claim 9 are dependent narrowing claims. They reduce the range of practice rather than expand it.
Claim-by-claim contraction
- Claim 2: specifies that the pharmaceutically acceptable acid addition salt is administered.
- Practically: reinforces salt administration as an infringement path.
- Claim 3: specifies hydrochloride salt.
- Practically: narrows to HCl salt.
- Claim 4: adds a “pharmaceutically acceptable carrier” limitation.
- Practically: covers formulation practice consistent with standard pharmaceutical carriers.
- Claim 5: limits administration to oral route.
- Practical impact: oral formulations are the clearest enforcement target; parenteral administration is outside this dependent claim set (though still potentially inside Claim 1 if Claim 1 is interpreted broadly on route, since Claim 1 does not restrict route).
- Claim 7: limits to a capsule or tablet dosage form containing the carrier.
- Practical impact: narrows to solid oral dosage forms.
- Claim 9: salt is hydrochloride in the context of Claim 5 (oral administration).
- Practical impact: strongest match for an oral HCl salt product in a solid carrier form.
Featured-snippet style answer
Claim 1 is the broadest method scope. Claims 2-3 focus on salt selection; Claims 4 and 8 add carrier and administration mechanics; Claims 5, 7, and 9 restrict route and dosage form to oral capsule/tablet formulations, with hydrochloride as a recurring narrow embodiment.
What does the formula (I) restriction do to infringement risk and design-around strategies?
The formula (I) language is the dominant scope limiter. In US patent enforcement, the accused product must match the claimed compound identity (or a pharmaceutically acceptable acid addition salt of it).
How competitors typically design around
- Different chemical entity: A non-matching scaffold generally avoids Claim 1.
- Different salt form: If the candidate is a different salt not considered “pharmaceutically acceptable acid addition salt” for that compound, it may fall outside Claims 2, 3, and 9 depending on how “pharmaceutically acceptable” and “acid addition salt” is construed.
- Different use framing: If the company does not “reverse” ethanol-related impaired mental alertness (for example, it claims different endpoints like sedation reversal or cognitive enhancement unrelated to ethanol impairment), it may avoid literal infringement of the method claim even if similar chemistry is used.
- Route/dosage avoidance: Claims 5 and 7 narrow oral capsule/tablet embodiments. Non-oral administration can attempt to fall outside those dependent claims, though Claim 1 could still capture non-oral administration unless Claim 1 is limited by claim construction of “method of reversing” to certain delivery contexts.
Practical business implication
Even if a candidate compound is close, the claim is not a broad “ethanol antidote” method. It is a “method using formula (I) compound or acid addition salts” with a specific outcome endpoint in humans.
How does “reversing impaired mental alertness effects of ethanol” constrain claim interpretation?
Functional endpoint and causation framing
The claim ties the treatment to reversal of ethanol’s mental alertness impairment in a human after alcohol consumption. This usually implies:
- The patent is aimed at post-consumption cognitive/alertness impairment rather than alcohol itself or purely pharmacokinetic reversal (e.g., elimination of ethanol).
- A successful defense against infringement arguments typically focuses on lack of “reversal” or lack of ethanol-specific mental alertness impairment as the targeted therapeutic endpoint.
Key litigation-relevant construction levers (what a court typically focuses on)
- whether “impairment” is tied to cognitive/alertness measures and whether the claimed effect is a therapeutic reversal, not correlation;
- whether the accused use is intended for humans who have “consumed alcohol” and addresses ethanol-related impairment.
What patent landscape exists for US 4,393,078 coverage beyond this single patent?
Because your request is constrained to US Patent 4,393,078 claim scope without providing the chemical identity of “formula (I)” (structure/compound name) and without providing any related publication numbers, continuations, divisionals, or assignees, a complete US landscape cannot be generated from the claim text alone without risking inaccuracies.
Given the constraints, this analysis focuses on the legal claim scope mechanics of US 4,393,078 and the enforcement implications that follow from its claim wording.
What are the likely infringement routes for formula (I) compounds and salts?
Route A: Direct inducement via labeled method of use
If an oral capsule/tablet product containing the formula (I) hydrochloride is marketed for reversing ethanol-related mental alertness impairment, the pathway aligns with:
- Claim 1 (broad method using compound or salt)
- Claim 3/Claim 9 (hydrochloride salt embodiment)
- Claim 5/Claim 7 (oral capsule/tablet carrier embodiment)
Route B: Product alone may not be enough
A product containing formula (I) might not infringe if it is not used for the claimed reversal purpose. Method claims generally focus on the “method of reversing” when performed on humans after alcohol consumption.
Route C: Salt form engineering
If competitors use alternative salt forms, they may attempt to avoid “hydrochloride” dependent claims. However, Claim 1 and Claim 2 could still capture “pharmaceutically acceptable acid addition salt thereof” if their salt is deemed pharmaceutically acceptable acid addition salt of the same compound.
What generic entry risks exist under this claim set?
Risk profile for generic small molecules
- If a generic applicant submits an ANDA for a product with the same formula (I) compound (or a pharmaceutically acceptable acid addition salt) and the reference listed drug’s labeling or proposed labeling explicitly supports use for reversing ethanol-impaired mental alertness, the risk rises substantially.
- If labeling is changed to exclude the reversal-of-ethanol-alertness method, the risk shifts from direct method infringement to arguments around induced infringement based on off-label promotion.
Risk for “new formulations” of same compound
Because Claim 4 and Claim 7 expressly cover carrier and capsule/tablet oral forms, formulation redesign to a different capsule/tablet format might not avoid Claim 1. It can reduce match to dependent claims but not necessarily the independent claim.
How strong is the patent estate for method scope based on claim wording alone?
On claim wording alone:
- Strength comes from the specific active constraint (formula I compound) and the specific therapeutic outcome constraint (reversing ethanol-impaired mental alertness). This narrows the field of captured products and uses.
- Vulnerability comes from the outcome framing being functional and tied to a specific clinical endpoint. If future evidentiary support or therapeutic framing diverges from “reversing impaired mental alertness effects of ethanol,” the practical enforceability against alternative uses may weaken.
Claim breadth summary (qualitative)
- Independent claim is moderately broad on administration mechanics (no explicit route limit in Claim 1), but strongly narrow on active identity and salt family.
- Dependent claims concentrate further on hydrochloride and oral solid dosage forms.
What regulatory and Orange Book exposure would align with this method claim?
This claim set is a method-of-use patent. Practical exclusivity and FDA labeling linkage would generally depend on whether the drug product is listed in the Orange Book with corresponding method-of-use patent entries and whether labeling reflects the claimed method.
However, without the drug name, application number, patent-to-Orange-Book listing mappings, or the compound identity of formula (I), a definitive Orange Book status cannot be produced without fabricating data.
How do you map the claims to a product commercial decision?
Infringement “yes/no” checklist based on claim language
A product and use are within strongest capture where all are true:
- Active ingredient is formula (I) compound or an acid addition salt thereof
- Use is in humans who have consumed alcohol
- Claimed effect is reversal of ethanol-related impaired mental alertness
- Use is oral (to match dependent claims 5/7) and ideally capsule/tablet (to match Claim 7)
- Salt is hydrochloride (to match Claims 3/9)
- The product uses a pharmaceutically acceptable carrier (to match Claim 4/8)
Commercial implication
Companies should treat the “method” framing and salt selection as key differentiators, not just chemical identity. If either chemical identity or the intended ethanol-impaired mental alertness reversal purpose is missing, the infringement match weakens.
Patent claim chart (text-grounded) for US 4,393,078
| Claim |
Required limitation (high-level) |
What an accused product/use must show |
| 1 |
Reverse ethanol-impaired mental alertness in a human who consumed alcohol; administer effective non-toxic amount of compound of formula (I) or pharmaceutically acceptable acid addition salt |
Candidate uses formula (I) compound/salt in an alcohol-after use setting with the reversal mental-alertness endpoint |
| 2 |
Salt form is administered |
Usage is specifically the acid addition salt (as administered) |
| 3 |
Salt is hydrochloride |
HCl salt used |
| 4 |
Administered with pharmaceutically acceptable carrier |
Pharmaceutical formulation includes acceptable carrier |
| 5 |
Administered orally |
Route is oral |
| 7 |
Capsule or tablet dosage form |
Oral solid capsule/tablet format |
| 8 |
Salt administered with pharmaceutically acceptable acid addition salt |
Salt administration emphasized in this dependent pathway |
| 9 |
Oral + hydrochloride salt |
Oral dosing with HCl salt |
Key Takeaways
- US 4,393,078 is a method-of-use patent centered on reversing ethanol-impaired mental alertness effects in humans by administering the formula (I) compound or pharmaceutically acceptable acid addition salt, using an effective non-toxic amount.
- Claim 1 is the enforcement anchor: it is broad on route in the claim text, but narrow on active identity and specific ethanol-related mental alertness reversal outcome.
- Dependent claims narrow the practical match to acid addition salts and repeatedly to hydrochloride, and further to oral dosing and capsule/tablet dosage forms.
- Design-around risk is primarily driven by whether the competitor’s compound is within formula (I) and whether labeling or promoted use matches the ethanol-impaired mental alertness reversal endpoint.
FAQs
1) What is the broadest claim in US Patent 4,393,078?
Claim 1, covering a method of reversing ethanol-impaired mental alertness by administering a non-toxic effective amount of the formula (I) compound or its pharmaceutically acceptable acid addition salt.
2) Do Claims 5 and 7 require oral administration and capsule/tablet dosing?
Yes. Claim 5 requires oral administration, and Claim 7 further requires a capsule or tablet containing a pharmaceutically acceptable carrier.
3) Does “hydrochloride” appear as an essential limitation anywhere?
Hydrochloride is required in Claims 3 and 9 (with Claim 9 combining hydrochloride with oral administration through Claim 5/9 dependency).
4) Can a different salt avoid infringement of the hydrochloride-dependent claims?
It may avoid Claims 3 and 9 specifically, but Claim 1 and Claim 2 can still capture use of other “pharmaceutically acceptable acid addition salts” of the same formula (I) compound.
5) Is the patent about reversing ethanol effects broadly or a specific outcome?
The claim language targets “reversing impaired mental alertness effects of ethanol,” which is a specific functional clinical endpoint tied to alcohol consumption and impairment of alertness.
References
- US Patent 4,393,078.
